Back to peptides

Selank

aka Selanc, TP-7, tuftsin analog

NootropicAnxietyCognitiveGabaImmune SupportSleep

Last reviewed April 27, 2026 by Doserr editorial team · 19 references on this page

Information on this page is sourced from published research and is for educational purposes only. It does not constitute medical advice.

TL;DR

  • What it is: A Russian-developed synthetic heptapeptide derived from the immune peptide tuftsin, approved in Russia for anxiety.
  • What it's used for: Studied for anxiolysis and cognitive support, primarily in Russian-language clinical and preclinical research.
  • Evidence level:limitedLimited -- nearly all human studies are Russian-only and lack accessible full methodology.

Dose at a glance

BeginnerCommonHigher end
Per dose250 mcg250-500 mcg500-750 mcg
Daily total250-500 mcg500-1,000 mcg900-1,350 mcg
Schedule1-2x daily2-3x daily3x daily
Cycle lengthDays to 2 weeks4-6 weeks on, 2-4 weeks offUp to 6 weeks, Russian approved protocol

Synthesized from community-reported ranges. Not a recommendation. Route varies by compound — see Common route in What people report below.

Half-life
Plasma half-life not characterized in any published peer-reviewed human pharmacokinetic study. Short systemic plasma half-life reported in Russian preclinical literature (minutes after IV dosing in animals), intranasal delivery is thought to achieve CNS penetration via olfactory pathways. No published PK data for t1/2, Cmax, or bioavailability by any route in humans.
Typical dose range
Doses below are from published research, not recommendations. Animal studies: 80-750 mcg/kg IP in rodent stress models (PMID: 32651826), 300 mcg/kg IP or SC in learning, memory, and anxiolytic rodent studies (PMIDs: 20919548, 31625062, 28280289, 36322304), 0.3 mg/kg IP in morphine withdrawal model (PMID: 36322304). Human comparative trials: intranasal approximately 900 mcg/day reported in one Russian study (full methodology only in Russian, PMID: 18454096). The approved Russian 0.15% nasal solution delivers approximately 75 mcg per drop.
Route
Intranasal (approved Russian formulation and human comparative studies), intraperitoneal (IP) in most rodent research. Subcutaneous (SC) also used in some animal studies and reported in community use.
Evidence tier
limited

Animal or in-vitro studies only — no published human efficacy data.

What the research shows

Each topic links to the studies behind it. Click a topic to expand.

What we don't know yet

  1. No Western-standard controlled efficacy trial published, Russian human studies lack accessible full methodology in English (PMIDs: 18454096, 25176261, 26356395)
  2. Human pharmacokinetics not characterized in any published peer-reviewed study, half-life figures in community use come from unpublished or non-English preclinical data
  3. Lack-of-dependence claim not verified by Western pharmacological standards, no published withdrawal or tolerance study using standardized methods
  4. Long-term human safety data absent, longest published treatment window is 14 days (PMIDs: 18454096, 18577961)
  5. Most research from a narrow group of Russian institutions, independent replication outside Russia is essentially absent
  6. A 2021 English-language review (Doyno CR & White CM, PMID: 34396551) classified Selank as 'poorly studied' and flagged its GABAergic mechanism and regulatory status outside Russia
  7. Intranasal pharmacokinetics and formulation equivalence for non-Russian-sourced compounded products not studied

Run a calculation for this peptide

Reconstitution math, both directions.

Track this peptide

Log every dose, see your history, and save this protocol with one click.